Loading…

KPIC006650.KSCompetitor analysis, valuation and peers

South Korea · KRW·Materials›Chemicals: Specialty
Momentum strong 67
Mkt cap
$405M
US dollars, full cap
Free float
54%
of shares outstanding
$/day
$2.52M
20-day average traded
Fwd P/E
8.9×
forward earnings
ROIC−WACC
-2.0 pp
WACC 6.0%
Hurdle
n/a
no reverse DCF
Next earnings
113 days
11 Mar 2027
Close · KRW₩88,400
1D+2.9%
1W-6.5%
1M+3.5%
3M-3.3%
6M-40.2%
YTD-39.0%
1Y-32.4%
ATR %5.9%
52w lowhigh56.4% off high

What KPIC does

Employees: 866

KPIC at a glance

Size KPIC (006650.KS) is a South Korea Materials company (Chemicals: Specialty) with a market value of $405M, the 399th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩88,400 on 18 Nov 2026.

Performance Over six months the shares fell 40.2%, against -12.5% for the median peer and -37.2% for the South Korea market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 11.0% over the last twelve months (peer median +8.8%); the operating margin is 3.9% (peer median 5.3%).

Valuation It trades at 8.9× forward earnings against a peer median of 22.3× (2nd cheapest of 9).

Capital Return on invested capital runs 2.0 points below its cost of capital (6.0% WACC).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 88006650.KS 63
Six months, rebased to 100: KPIC against the median of its 20 peers (local-currency closes).

KPIC financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩3.56T₩3.35T₩2.80T₩2.50T₩2.22T
Revenue growth—+20%+12%+13%—
Gross profit₩215B₩116B-₩10.2B-₩12.7B-₩172B
EBITDA₩290B₩222B₩120B₩119B-₩53.7B
Net income₩63.7B₩31.7B-₩8.53B-₩29.0B-₩149B
Free cash flow-₩16.0B₩126B₩74.4B-₩27.4B-₩395B
Capital expenditure₩106B₩78.3B₩58.9B₩115B₩348B
Total debt₩486B₩307B₩198B₩155B₩88.7B

Quarterly statements and history in the cockpit →

KPIC competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%0013673002396037981710002666000707VISHNUTATVAELLENGEVOBAK30013200133517144097688203300927603725603192006650.KS6-month return →1-month return →
Up and to the right = strong over both horizons. KPIC is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%0×20×40×1710VISHNUTATVAELLENGEVOBAK300132688203006650.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. KPIC is the large dot.

KPIC competitors and peer comparison

How KPIC compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

KPIC against its 20 peers (data as of 18 Nov 2026)
Measure006650.KSPeer medianRank in peer set
1-month return+3.5%-10.9%3rd highest of 21
6-month return-40.2%-12.5%4th lowest of 21
Distance from 52-week high-56.4%-41.5%2nd lowest of 21
Revenue growth (TTM)+11.0%+8.8%9th highest of 21
Operating margin3.9%5.3%10th lowest of 21
Forward P/E8.9×22.3×2nd cheapest of 9
ROIC minus cost of capital-2.0 pp-2.9 pp9th highest of 21
EV / EBITDA3.1×14.5×2nd cheapest of 7
Net debt / EBITDA0.3×2.4×3rd least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
KPIC 006650.KSSouth Korea$405M-40%+11%4%8.9×n/an/a
Zhejiang Haisen Pharmaceutical 001367.SZChina$404M-24%+9%29%n/a-3.9%+13.4%
Baotou Dongbao Bio-Tech 300239.SZChina$408M-14%+7%7%n/an/an/a
Qingdao Copton Technology 603798.SSChina$401M-43%-7%5%n/a19.9%+0.9%
Oriental Union Chemical 1710.TWTaiwan$409M+41%+1%0%16.1×n/an/a
Guangdong Delian 002666.SZChina$410M-30%+3%0%n/an/an/a
Hubei Shuanghuan Science and Technology 000707.SZChina$399M-11%-10%-10%n/a56.5%+3.1%
Vishnu Chemicals VISHNU.NSIndia$398M-8%+14%13%20.1×n/an/a
Tatva Chintan Pharma Chem TATVA.NSIndia$412M+29%+50%13%49.8×n/an/a
Ellenbarrie Industrial Gases ELLEN.NSIndia$420M0%+289%28%24.6×42.8%+14.3%
Gevo GEVOUnited States$421M+4%+80%-11%24.8×n/an/a
Braskem S.A. Sponsored ADR Pfd BAKUnited States$421M-82%-1%1%1.6×n/an/a
FuJian Nox Bellcow 300132.SZChina$422M-32%+18%7%16.5×-4.3%-10.5%
Trust Chem 001335.SZChina$388M-40%+5%7%n/a24.6%+5.6%
Ho Tung Chemical 1714.TWTaiwan$388M+40%+48%10%n/a-20.6%-1.5%
Koatsu Gas Kogyo 4097.TJapan$423M+10%+4%7%n/a-9.6%+5.1%
Zhejiang Hisun Biomaterials 688203.SSChina$386M-5%+47%4%45.7×12.5%+26.6%
Nantong Jiangtian Chemical 300927.SZChina$425M-32%+51%5%n/a16.3%+29.0%
Guangdong Tianan New Material 603725.SSChina$425M-10%-12%2%n/a19.4%+29.0%
Shanghai Huide Science & Technology 603192.SSChina$426M-22%+10%3%n/a9.0%+10.5%
Advansix ASIXUnited States$380M-34%+8%-1%n/a52.9%+5.6%

Questions

Which companies are KPIC's closest peers?
The cockpit's peer set: Zhejiang Haisen Pharmaceutical (001367.SZ), Baotou Dongbao Bio-Tech (300239.SZ), Qingdao Copton Technology (603798.SS), Oriental Union Chemical (1710.TW), Guangdong Delian (002666.SZ), Hubei Shuanghuan Science and Technology (000707.SZ), Vishnu Chemicals (VISHNU.NS), Tatva Chintan Pharma Chem (TATVA.NS).
Is KPIC expensive compared with its peers?
On forward p/e it trades at 8.9× against a peer median of 22.3×, 2nd cheapest of 9 in its peer set.
How has KPIC stock performed?
Over six months to 18 Nov 2026 the shares returned -40.2% against -12.5% for the median peer; over one year -32.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.